

Award Number: W81XWH-10-1-0915

TITLE: Exploitation of P-glycoprotein Over-expression for Targeted Drug Delivery to Breast Cancer

PRINCIPAL INVESTIGATOR: David Putnam

CONTRACTING ORGANIZATION: Cornell University
Ithaca, NY 14853

REPORT DATE: October 2011

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE October 2011			2. REPORT TYPE Final		3. DATES COVERED 15 September 2010-14 September 2011	
4. TITLE AND SUBTITLE Exploitation of P-Glycoprotein Over-expression for Targeted Drug Delivery to Breast Cancer					5a. CONTRACT NUMBER	
					5b. GRANT NUMBER W81XWH-10-1-0915	
					5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) David Putnam E-Mail: dap43@cornell.edu					5d. PROJECT NUMBER	
					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Cornell University, Ithaca, NY 14853					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT This research resulted in the design and synthesis of new nanoconjugates with the ability to target multidrug resistant tumors. Additionally, the work has helped to initiate a new research program focused on the delivery of drugs to the brain. Both tracks of research are continuing in the PI's laboratory. Most surprisingly, we discovered that a simple P-gp substrate that has no other pharmacological effects, is easily conjugated to the delivery system and effectively targets MDR cells. This is particularly exciting because for drug targeting to the brain, having minimal off-target pharmacological activity is important toward the development of an effective delivery vehicle (i.e., low side effects).						
15. SUBJECT TERMS Multidrug resistance, nanoconjugate, targeted drug delivery						
16. SECURITY CLASSIFICATION OF:				17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	19b. TELEPHONE NUMBER (include area code)			
				UU	6	

Table of Contents

	<u>Page</u>
Introduction.....	1
Body.....	2 - 5
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusion.....	6
References.....	6
Appendices.....	6

1. Introduction

The premise of the proposed research was to utilize the efflux pump mechanism of P-glycoprotein to target drug-containing particles to multidrug resistant cells. Conceptually, the proposed targeting mechanism is shown in cartoon form in Figure 1. The idea represents a new way of thinking about how to use P-gp as a targeting opportunity. Generally the efflux activity of P-gp is considered a detriment to the treatment of tumors because it actively removes the anticancer agents from the cytosol of the cell. However, using the targeting paradigm shown in Figure 1, the proposed research aims to use P-gp as an opportunity to selectively target and kill cells that express the protein.




Figure 1. Tethering of drug delivery carriers to cells through interaction with P-gp. (A) Drug carrier with PEG linker and P-gp substrate, Rho123. (B) PEG linker spans membrane as Rho123 diffuses into cell. (C) Export of Rho123 by P-gp tethers drug carrier to cell.

The hypothesis for the research, as originally written in the IDEA proposal was that drug targeting to breast cancer can be mediated by cells that overexpress P-gp, and the P-gp anchored drug carrier can improve the therapeutic efficacy of the anticancer drugs. The overall purpose of the grant was to exploit P-gp as a cell-type specific target for the targeted treatment of breast cancer.

The Specific Aims of the research were:

- 1) to design and create drug delivery carriers targeted to cells that overexpress P-glycoprotein
- 2) to demonstrate P-gp specific binding of drug delivery carriers to breast cancer cells *in vitro*

Each Specific Aim was successfully completed, as shown in the research accomplishments section below.

2. Body

Specific Aim 1: to design and create drug delivery carriers targeted to cells that overexpress P-glycoprotein

The synthesis of PEG tethered to the P-gp substrate, rhodamine123 was conducted as shown in Figure 2. Confirmation of the conjugate structure was determined by ^1H NMR (Figure 3)




Figure 2. Conjugation reaction of biotin-PEG-NH₂ to the P-gp substrate, rhodamine 123. All reactions were carried out in dimethylformamide (DMF) in the presence of excess triethylamine. A 3:1 mol ratio of rho 123:NH₂ was used. Purification was conducted by dialysis against distilled water, and final chemical structure determined by ^1H NMR




Figure 3. ^1H NMR showing 94% conjugation. (*) the peak from biotin (**) peak from rhodamine 123, integrated peak area used to calculate percent conjugation

The model delivery system consisted of the biotin-PEG-Rho123 conjugate attached via the avidin-biotin link to fluorescently labeled avidin-coated polystyrene beads. The beads allow the visualization of the system by fluorescent microscopy thereby allowing the quantitation of binding in the follow-on flow chamber experiments (Specific Aim 2). A cartoon representation of the final conjugate is provided in Figure 4.




Figure 4. Fluorescent polystyrene nanoparticle used for initial targeting studies. Targeted form includes a rho123 end group. Untargeted control contains a CH₃ end group.

Specific Aim 2: to demonstrate P-gp specific binding of drug delivery carriers to breast cancer cells *in vitro*

Flow chamber experiments were conducted to determine the binding capacity of the P-gp particles to P-gp expressing breast cancer cells compared to non-P-gp expressing breast cancer cells. The configuration of the flow chamber is provided in Figure 5.




Figure 5: Schematic diagram of a circular parallel-plate flow chamber. Cells are grown on a glass surface over which a gasket is placed allowing the flow of reagents over the top of the cells. Attachment of beads to the cell surface is quantified by use of a fluorescent microscope positioned above the flow chamber visible window.

The MCF-7 breast adenocarcinoma cell line, engineered to either express P-gp (MCF-7/Mdr1) or not express P-gp (MCF-7/wt) were grown on the surface of a glass plate. Expression or absence of P-gp in each cell line was determined by Western blot analysis (Figure 6).




Figure 6: Western blot showing P-gp over expression in MCF7-P-gp(+) cells compared to positive control CACO-2 cells and negative control MCF7-P-gp(-) cells.

FACS analysis was used to quantify the number of targeted and untargeted beads to both P-gp expressing and P-gp non-expression cells (Figure 7).




Figure 7: FACS data in initial in vitro targeting studies. (a) MCF7-P-gp(-) cells (b) MCF7-P-gp(-) cells with control beads (c) MCF7-P-gp(-) cells with rho 123 beads (d) MCF7-P-gp(+) cells (e) MCF7-P-gp(+) cells with control beads (f) MCF7-P-gp(+) cells with rho 123 beads

From the flow chamber data, the total number of bound beads were quantified (experiments conducted in triplicate). The output from the experiment is shown in Figure 8 below.




Figure 8: Flow chamber data from flow chamber studies. The results show that control beads (without rhodamine) do not adhere to either P-gp expressing or P-gp expressing MCF-7 cells, whereas beads containing rhodamine123 adhere to P-gp expressing MCF-7 cells, but not to non-expressing cells. Collectively these data demonstrate the feasibility of using P-gp substrates to target MDR(+) tumors.

Lastly, the kinetics of rhodamine binding to MDR(+) cells (i.e., MCF-7/Mdr1) was determined over a 30 min timeframe (Figure 9). The data reveal a rapid binding curve followed by an approximately first-order elimination followed by a steady state concentration. These data suggest a potential validation of the “fishing hook” hypothesis for how these conjugates bind to P-gp(+) cell lines.




Figure 9: Binding kinetics profile of rhodamine-targeted beads to MCF-7/Mdr1 cells.

3. Key research accomplishments

Each proposed Specific Aim was successfully completed. The conjugation of a P-gp substrate to PEG-biotin allowed the formulation of polystyrene beads with the ability to selectively bind to P-gp(+) cells. The degree of binding was successfully quantified using a flow chamber mounted to a fluorescent microscope and FACS. Collectively, these data suggest that a P-gp substrate can be successfully used to selectively target P-gp(+) cell types.

4. Reportable outcomes

The output from these successful experiments demonstrate the feasibility to selectively target drug-conjugates to P-gp(+) cell types. This is the first demonstration of the utilization of P-gp as a targeting receptor.

5. Conclusions

The data resulting from the two Specific Aims strongly support, for the first time, the validity of utilizing P-gp substrates as agents for targeting P-gp(+) cell types.

6. References

None required for this work. This is the first example of using P-gp substrates as a targeting agent.

7. Appendices

None.